Interferon alpha-2b inhalation - BioSante Pharmaceuticals

Drug Profile

Interferon alpha-2b inhalation - BioSante Pharmaceuticals

Latest Information Update: 30 Jul 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator BioSante Pharmaceuticals
  • Developer ANI Pharmaceuticals
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Hepatitis B; Hepatitis C

Most Recent Events

  • 17 Apr 2016 Biomarkers information updated
  • 18 Jul 2013 BioSante Pharmaceuticals is now called ANI Pharmaceuticals
  • 18 Jul 2013 Discontinued - Clinical-Phase-Unknown for Hepatitis B in USA (Inhalation) prior to July 2013
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top